AnteoTech (ADO) Q1 2027 TU earnings summary

Executive summary

• Quarter focused on commercial execution, customer validation and sales conversion across Advanced Battery Technologies and Life Sciences.

• Key milestones included the Xerabrid collaboration, Airspeeder supply agreement, product launches at ADLM 2026 and completion of the initial CLIA development stage.

• A$1.9m R&D Tax Incentive receipt supported a quarter-end cash balance of A$11.0m; no bank debt, excluding lease and asset-finance liabilities.

Financial highlights

• Customer receipts were A$200k for the quarter, including A$134,138 from Serum Institute of India, recognised as FY2027 revenue.

• Net operating cash outflow was A$28k after receiving A$1.906m in government grants and tax incentives; investing outflow was A$135k and financing outflow A$41k.

• Cash and cash equivalents were A$10.997m at quarter end, including A$5.5m in a six-month term deposit; cash at the start of the quarter was A$11.201m.

• Operating payments included A$1.066m staff costs, A$581k administration and corporate costs, A$187k R&D and A$156k advertising and marketing.

Outlook and guidance

• FY2027 priorities are converting evaluations into sales, expanding the pipeline and securing strategic partnerships across both business units.

• Advanced Battery Technologies plans to dispatch Xerabrid separator samples to seven prospective manufacturers and OEMs, advance two Ultranode 95 JDA negotiations and pursue commercial supply agreements for Anteo C.

• Life Sciences plans to qualify ADLM and MEDICA leads, commence independent validation programs and expand international marketing.

• ARENA extended the initial grant milestone deadline by six months, to 13 May 2027, allowing more time for strategic discussions.